Gene expression profiling in the myelodysplastic syndromes.

Gene expression profiling in the myelodysplastic syndromes.

The myelodysplastic syndromes (MDS) are a heterogeneous group of haematopoietic malignancies, characterized by blood cytopenias, ineffective hematopoiesis and hypercellular bone marrow. Several genetic alterations have been reported in MDS but these are not MDS-specific and the underlying molecular...

Bibliográfalaš dieđut
Váldodahkkit:	Pellagatti, A, Fidler, C, Wainscoat, J, Boultwood, J
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2005

Geahča maid

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2003)

Telomere length in myelodysplastic syndromes.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (1995)

Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders
Dahkki: Zhang, J, et al.
Almmustuhtton: (2004)

Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2004)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2008)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2004)

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2006)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2004)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2010)

Clonality in the myelodysplastic syndromes.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2001)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2006)

Molecular pathogenesis of the myelodysplastic syndromes
Dahkki: Boultwood, J, et al.
Almmustuhtton: (1999)

Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
Dahkki: Watkins, F, et al.
Almmustuhtton: (2004)

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE IN MYELODYSPLASTIC SYNDROMES - REPLY
Dahkki: Boultwood, J, et al.
Almmustuhtton: (1991)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2005)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2007)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2016)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2009)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2010)

Telomere length in myelodysplastic syndromes.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (1997)

Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q)
Dahkki: Boultwood, J
Almmustuhtton: (2009)

SF3B1 mutant myelodysplastic syndrome: Recent advances
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2020)

8 Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q)
Dahkki: Boultwood, J
Almmustuhtton: (2009)

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Dahkki: Fidler, C, et al.
Almmustuhtton: (2004)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
Dahkki: Armstrong, R, et al.
Almmustuhtton: (2017)

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2007)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2014)

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2013)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2009)

The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
Dahkki: Fidler, C, et al.
Almmustuhtton: (1999)

Structure of the granulocyte macrophage colony-stimulating factor gene in patients with the myelodysplastic syndromes.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (1990)

Gene expression profiling in polycythemia vera using cDNA microarray technology.
Dahkki: Pellagatti, A, et al.
Almmustuhtton: (2003)

5q- syndrome.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2012)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Dahkki: Fernandez-Mercado, M, et al.
Almmustuhtton: (2010)

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Dahkki: Fernandez-Mercado, M, et al.
Almmustuhtton: (2013)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
Dahkki: Jadersten, M, et al.
Almmustuhtton: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
Dahkki: Boultwood, J, et al.
Almmustuhtton: (2012)

Neutrophil gene expression in chronic myeloproliferative disorders.
Dahkki: Eagleton, H, et al.
Almmustuhtton: (2003)